Inconsistencies in the red blood cell membrane proteome analysis: generation of a database for research and diagnostic applications. by Hegedus, T. et al.
Original article
Inconsistencies in the red blood cell membrane
proteome analysis: generation of a database for
research and diagnostic applications
Tama´s Hegedu†s1,2,*,#, Pururawa Mayank Chaubey3,#, Gyo¨rgy Va´rady4,
Edit Szabo´4, Hajnalka Saranko´1,2, Lia Hofstetter3, Bernd Roschitzki5,
Bruno Stieger3 and Bala´zs Sarkadi2,4
1MTA-SE Molecular Biophysics Research Group, Hungarian Academy of Sciences, Tu†zolto´ u. 37-47,
H-1094 Budapest, Hungary, 2Department of Biophysics and Radiation Biology, Semmelweis University,
Tu†zolto´ u. 37-47, H-1094 Budapest, Hungary, 3Department of Clinical Pharmacology and Toxicology,
University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland, 4Institute of Enzymology,
Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudo´sok ko¨ru´tja 2,
H-1117 Budapest, Hungary and 5Functional Genomics Center Zurich, University of Zurich, ETH Zurich,
Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
#These authors contributed equally to this work.
*Corresponding author: Tel/Fax: þ36 1 3724353, Email: hegedus@hegelab.org
Correspondence may also be addressed to Bruno Stieger, Tel: þ41 44 6343169, Email: bstieger@kpt.uzh.ch
Citation details: Hegedu†s,T., Chaubey,P.M., Va´rady,G., et al. Inconsistencies in the red blood cell membrane proteome
analysis: generation of a database for research and diagnostic applications. Database (2015) Vol. 2015: article ID bav056;
doi: 10.1093/database/bav056
Received 6 January 2015; Revised 11 May 2015; Accepted 12 May 2015
Abstract
Based on recent results, the determination of the easily accessible red blood cell (RBC)
membrane proteins may provide new diagnostic possibilities for assessing mutations,
polymorphisms or regulatory alterations in diseases. However, the analysis of the cur-
rent mass spectrometry-based proteomics datasets and other major databases indicates
inconsistencies—the results show large scattering and only a limited overlap for the
identified RBC membrane proteins. Here, we applied membrane-specific proteomics
studies in human RBC, compared these results with the data in the literature, and gener-
ated a comprehensive and expandable database using all available data sources. The
integrated web database now refers to proteomic, genetic and medical databases as
well, and contains an unexpected large number of validated membrane proteins previ-
ously thought to be specific for other tissues and/or related to major human diseases.
Since the determination of protein expression in RBC provides a method to indicate
pathological alterations, our database should facilitate the development of RBC mem-
brane biomarker platforms and provide a unique resource to aid related further research
and diagnostics.
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Introduction
A significant portion (30%) of the human proteome con-
sists of membrane proteins and their mutants and poly-
morphic variants are involved in numerous diseases
providing the molecular targets of most of the marketed
drugs (1, 2). Due to a multi-step processing and complex
regulation of membrane protein expression, in most cases
the DNA or mRNA-based information cannot provide
appropriate diagnostic information, and only direct pro-
tein determinations can serve as proper medical bio-
markers. However, tissue sample collection, and the lack
of accuracy and sensitivity for quantitative membrane pro-
tein detection are the limiting factors in this regard.
A major set of membrane biomarkers is provided by the
Cluster of Differentiation (CD) system (see http://www.
hcdm.org), mostly applied in haematology and immun-
ology. This set [continuously updated and supervised by
the Human Cell Differentiation Markers Workshop (3, 4)]
contains now over 500 cell surface markers, including
glycoproteins, glycosylated lipids and carbohydrates, all
playing important roles in cell function, differentiation and
activation. The main advantage of the CD system is that its
markers can be detected by validated antibodies and some
of them (although still a minority) are routinely used in
diagnostic laboratories. Thus, the results provide valuable
information of disease states even without knowing the
exact identity and function of a given marker. However, a
major limitation of this system for membrane proteins is
that it includes only those recognized by well-described
antibodies, and the quantitation of the CD marker in most
cases is inappropriate.
Mass spectrometry-based proteomics may provide both
qualitative and quantitative data for membrane protein
expression. However, integral membrane proteins are vari-
ably recognized by these methods and further difficulties
are related to the sampling and quantification of large and
hydrophobic membrane proteins (5–8). Since most of the
MS approaches do not focus on membrane proteins, they
have an inevitable bias towards cytoplasmic proteins. In
addition, the need of expensive major equipment hinders
their wide-spread diagnostic applications in routine clinical
laboratories.
In the case of the human red blood cells (RBCs), the
limitations of tissue sample collection and continuous
intracellular membrane protein trafficking are not affect-
ing membrane protein determinations. Small blood sam-
ples are easy to collect and contain a relatively large
number of RBC (about 5 l06 cells/ml), which have only a
single plasma membrane. Several recent studies suggest
that uncovering the red cell membrane proteome may pro-
vide the basis of valuable diagnostic tools (9–11).
However, even highly purified RBC samples may contain
immature or contaminating cells, and minor contaminants
may have a major impact on the results of proteomics.
Thus, a vigorous control is necessary in this regard.
There have been numerous studies using different
approaches (e.g. MS, 2D electrophoresis and antibody
detection) attempting to describe the RBC membrane
proteome (8, 11). CD markers for the RBC are available,
and the blood group systems are also provided in major
databases. Surprisingly, we found major inconsistencies in
these data, thus their medical diagnostic use is hampered
by the contrasting findings, the ambiguous protein names,
outdated database identifiers and the variable format of
data. Mining information on RBC proteins from laborious
reviews merging data from different studies (6, 10) is still
extremely difficult, and currently there is no available cen-
tral and searchable database for the membrane proteins
expressed in RBCs.
In this study, we aimed to generate a tool for the per-
sonalized medical diagnosis of diseases associated with
membrane proteins, by establishing an integrated
platform of the RBC membrane proteome. First, we per-
formed MS studies on human RBC membrane prepar-
ations which were further washed in alkaline milieu to
remove cytoplasmic and extracellular adhering proteins.
Later, we compared our dataset with other MS-based, CD
cluster-defined and blood group-specific databases. Based
on these results, we have generated an integrated database
based on various RBC-relevant sources, for a research
and diagnostic biomarker application of the RBC mem-
brane proteome.
Methods
MS analysis of red cell membrane proteins
RBC ghost preparation
Membrane was prepared from 50 ml of blood provided by
healthy donors with a written consent in a project with
approved ethical committee permission. This study was
approved by the regional ethical committees (Department
of Health, Office of Hungarian Government, Budapest,
Hungary), and all procedures were performed in
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accordance with the Declaration of Helsinki. RBC was iso-
lated and RBC membranes (ghosts) were prepared accord-
ing to the original methods described by Schatzmann and
Rossi (12) and Wolf (13). These processes involved the
removal of contaminating cells, including platelets and
white-blood cells (confirmed by flow cytometry examin-
ations), during several washes of the red blood cells. In the
flow cytometry measurements, RBCs were labelled with
WGA-Alexa488, while Draq5 nuclear stain was used to
visualize all white blood cells. For selectively labelling the
platelets, an FITC-conjugated anti-CD61 antibody was
applied. We found that after three washes of the blood
samples, the RBC/total WBC ratio decreased from an ori-
ginal mean value of 0.27 to 0.0002%, while the RBC/
platelet ratio decreased from a mean of 2.47 to 0.011%.
This means the presence of about 2 WBC/106 RBC, and
about 1 platelet/104 RBC in the final RBC preparation.
Potential reticulocyte contamination was also examined by
Giemsa staining of the RBC preparation, and reticulocyte
count after three washes (removing the upper layer of
RBCs) decreased from 2 to <0.02%. In order to remove
any membrane-associated cytoplasmic or plasma proteins
from ghosts, the white RBC membranes (5 mg protein/ml)
were diluted with 20-fold volume of 0.5 mM Tris/HCl,
0.05 mM DTT (pH 8.5), incubated for 30 min at 4C and
for 15 min at 37C, then homogenized with a 27-gauge
needle. The membranes were further washed first with
10 mM Tris/HCl, 0.5 mM EDTA, pH 8.0 and then twice
with large volumes of 10 mM Tris/HCl, pH 7.4. The mem-
branes were resuspended at 2 mg protein/ml in 140 mM
KCl and 20 mM Tris/HCl, pH 7.4 and kept frozen until
further use.
Membrane protein extraction
Erythrocyte membrane (ghost) extraction with carbonate
to remove adhering proteins was performed according to
Fujiki et al. (14) in the presence of Mini complete protease
inhibitor (Roche Applied Biosystems, Switzerland) for 1 h
at 4C. Extracted membranes were collected after ultracen-
trifugation for 1 h at 100 000gav. The supernatant was dis-
carded and the pellet was resuspended in 200ml sucrose
(250 mM) using a syringe with a 25-gauge needle. The
protein estimation was carried out using BCA protein
assay kit (Interchim, France).
In-solution digestion
200mg of protein was first deglycosylated with PNGase
F (NEB) at 37C [overnight at 500 rpm, at RT (15)]. The
sample was diluted with 20 mM ammonium bicarbonate
(pH 8) and 0.1% Rapigest SF surfactant (Waters, USA).
The proteins were reduced using 5 mM DTT (30 min at
60C, 700 rpm) followed by alkylation with 45 mM
iodoacetamide (10 min at RT in the dark). The reaction
was quenched by adding 30 mM DTT (10 min at RT). The
resulting sample was first digested using trypsin (sequenc-
ing grade; Promega, Switzerland) at a ratio of 1:20 (3.5 h
at 37C at 700 rpm) followed by centrifugation for 10 min,
13 000 g) and supernatant (S1) was collected. The pellet
was further digested with chymotrypsin and trypsin at a
ratio of 1:1 (overnight at 37C at 700 rpm). The reaction
was stopped by adding 50% acetonitrile and 0.1% tri-
fluroacetic acid (37C, 30 min at 700 rpm) and the super-
natant was collected (S2). S1 and S2 were pooled for
further analysis.
Pre-fraction by Strong Cation Exchange (SCX)
Peptides obtained above were vacuum dried, resuspended
in buffer A (10 mM KH2PO4, pH 2.7, in 25% acetonitrile),
and loaded onto a 2.1 200 mm polysulfoethyl asparta-
mide A column (PolyLC, USA) on an Agilent HP1100 bin-
ary HPLC system (Agilent Technologies, USA). Peptides
were eluted with an increasing KCl gradient (10–40 min,
0–30% buffer B; 40–60 min 30–100% buffer B; 10 mM
KH2PO4, pH 2.7 and 500 mM KCl in 25% acetonitrile)
and fractions of 0.6 ml collected. Eluted peptides were
pooled into 17 fractions based on the chromatogram, and
desalted using Ziptips (Millipore, Switzerland) following
the vendors protocol.
MS analysis
Desalted samples were vacuum concentrated and resus-
pended in 3% acetonitrile and 0.1% formic acid, before
injecting on LTQ Orbitrap XL mass spectrometer (Thermo
Fischer Scientific, Germany) coupled to an Eksigent nano
LC system (Eksigent Technologies, USA). Peptide separ-
ation was made using self-packed (75 mm 80 mm) reverse
phase column packed with C18 material (AQ 3 mm, 200 A;
Bischoff GmbH, Germany) as previously described in
Mayank et al. (16).
Data refinement
After data collection peak lists were generated using
Mascot Distiller 2.3 (Matrix Science Inc., UK) and
searched against a human database from SwissProt (release
December 2012) concatenated with its decoyed version
and an in-house build contaminant database using the
Mascot search algorithm (Mascot 2.3; Matrix Science Inc.,
UK). The following search parameters were used: precur-
sor ion mass tolerance 10 ppm; fragment ion mass toler-
ance 0.8 Da; trypsin digestion (one missed cleavage
allowed); fixed modifications of carbamidomethyl of cyst-
eine; variable modification oxidation of methionine as well
as pyro-Glu formation of peptide N-term glutamine. After
the Mascot search data were further evaluated using
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Scaffold 4.3 (Proteome Software Inc., OR, USA).
Thresholds for protein identification were set to 95% pro-
tein probability; 99% peptide probability and two peptides
per protein. Final data processing was carried out using
Microsoft Excel 2010 (Microsoft Corp) and presented in
the Figure 1 and Supplementary Table S1.
Database development and analysis
Semi-automatic data mining
To identify a protein from different data sources, gene
names and identifiers (e.g. IPI, UniProtKB, etc.) were
queried in different ways. In the case of publications, the
pdf file of the supplementary tables was converted to html
format, while in the case of a web resource (e.g. hRBCD,
BGMUT) contents were downloaded in html or text for-
mat. Python scripts were written and used to map gene
names and identifiers to unique, when possible reviewed,
UniProtKB entries. When this process failed, we tried to
assign gene names or database identifiers manually to
UniProtKB records. For example, in the case of unmatched
IPI (International Protein Index) identifiers, different ver-
sions of the retired IPI database were downloaded (http://
www.ebi.ac.uk/IPI) and searched. To convert GI numbers
to UniProt accessions, the mapping API of UniProtKB was
employed. In certain, relatively low number of cases our
efforts to identify the target protein unambiguously failed
because of obsolete entries and retired databases that are
not existing or maintained any more.
Software and tools
Membrane and membrane associated proteins were visual-
ized using various online resources: TMHMM2.0 (1),
Protter (17) (http://wlab.ethz.ch/protter/start/), data from
The Human Transmembrane Proteome Database (http://
htp.enzim.hu), and different sections of UniProtKB includ-
ing ‘Subcellular location’ and ‘Features’ were considered.
The database uses the MySQL relational database back-
end (http://www.mysql.com) for data storage. For data
access, the SQLAlchemy (http://www.sqlalchemy.org)
object-relational mapper libraries were used. The web
interface was created based on the TurboGears web frame-
work (http://turbogears.org) and the Genshi templating
library (http://genshi.edgewall.org). Selected data fields of
UniProtKB (18) presented in the entry page of a protein are
stored in a highly organized relational way, while the
whole UniProtKB records are stored in a separate table,
used exclusively for full text searches. Full text data from
the sources were also inserted for certain proteins when it
was possible [e.g. in the case of BGMUT (19)]. To aid
searches for proteins connected to diseases, we included
OMIM (Online Mendelian Inheritance in Man, OMIMVR .
McKusick-Nathans Institute of Genetic Medicine, Johns
Hopkins University, Baltimore, MD, http://omim.org)
data, mapped to protein entries for full text query possibil-
ity. Information about isoforms identified in our MS
experiments is also inserted and made searchable. Data
analysis was performed using python scripts and the
R statistical package.
Results and discussion
MS analysis of human RBC membranes and
database comparisons
When searching for the presence of red cell membrane pro-
teins in MS datasets on RBC, significant differences in the
identified proteins between various MS studies were
observed (see below). In order to test for the presence of
membrane proteins and to understand the possible sources
of differences, an MS-based proteomics study on isolated
membranes (ghosts) of human RBCs was performed in
house. The preparation method (see ‘Methods’ section)
was selected based on previous experience that this
approach removes contaminating cell types and loosely
membrane-bound cytoplasmic or plasma proteins most ef-
ficiently. In order to assess the quality of our MS data, a
comparative analysis with published human peripheral
blood constituents proteome (20) with a particular
emphasis on proteins known to be expressed in potentially
contaminating membranes. This analysis revealed that
most of the identified proteins in our study are not pre-
sent in blood constituents other than erythrocytes
(Supplementary Figure S1; Table 2) and that the level of
contamination with non-RBC markers was minimal (21).
As an important technical point, in order to try to enhance
the efficacy of proteolysis in our MS studies, we included
extensive deglycosylation of the proteins and screened for
the most optimal proteolysis conditions (22).
Three independent experiments were performed to
detect membrane proteins, and the data are presented in
Figure 1. We have identified altogether 419 proteins, 264
of them had predicted transmembrane domains or were
labelled as membrane-associated proteins in SwissProt
(Figure 1A and B). These 264 ‘membrane’ proteins found
in our MS study could be classified as integral, transmem-
brane (TM) proteins (167), and membrane-associated (97)
proteins. The other identified proteins in our RBC mem-
brane preparations are probably soluble proteins, variably
attaching to the membrane (155). Regarding the trans-
membrane proteins, in the three preparations we found
143–144–132 TM proteins, from which 115 were found in
all three membrane preparations (Figure 1C). The small
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differences of the samples may result from both technical
reasons and differences in protein expression of individual
blood donors.
In the following, we have made a detailed comparison
of our MS study results with various available data sour-
ces. The largest and most complete datasets of the erythro-
cyte membrane proteins can be found in MS-based studies.
However, when we analysed several of the most compre-
hensive MS-based datasets (6, 7, 10), we found only scat-
tered overlaps (Figure 2).
Interestingly, out of the 264 membrane proteins identi-
fied in our current MS experiments, a relatively high num-
ber of proteins (141) were not listed in hRBCD, and 131
were not found in the dataset of Pesciotta et al. (11) In con-
trast, our study could not detect 86 proteins out of the 209
membrane proteins listed in hRBCD and 171 out of the
304 proteins listed by Pesciotta et al (11) (Figure 2A).
Our analysis of these and other MS-based data from
publications (21, 23) was rendered to be more difficult or
impossible in certain cases. An incomplete list of challenges
includes identifiers pointing to non-human (e.g. rabbit,
dog, mouse) protein entries, different GI numbers listed
but pointing to the same gene, some of the GI numbers
listed which do not match the corresponding UniProtKB
accession listed in the same Supplementary table, etc.
Therefore we turned to reviews that already processed
various MS-based studies. A major MS-based list of red
cell membrane proteins has been compiled by
D’Alessandro et al. (6) Although this list contains 512
membrane proteins, 125 proteins found in our study are
not present in this dataset (Figure 2B). The recent RBC
protein collection by Goodman et al. (10) lists 687 poten-
tial membrane proteins, with 85 unique entries, still leav-
ing out a high number of RBC membrane proteins found
in other sources we investigated (Figure 2B).
The RBC membrane proteins included in the CD system
for erythrocyte antigens (http://www.hcdm.org), and pro-
teins providing the molecular basis of blood group anti-
gens, compiled in the human blood group database
(BGMUT) at the NCBI web site (19) (http://www.ncbi.
nlm.nih.gov/projects/gv/rbc/xslcgi.fcgi?cmd¼bgmut/home)
provide additional data sources in this regard. In both
cases cell surface expressed proteins are validated by anti-
bodies, and in many cases the related genetic background,
modification patterns, etc. are also provided. Again, in a
comparative analysis, we found that the CD list (contain-
ing 30 RBC membrane proteins) has 25 unique entries rela-
tive to all other databases, and the BGMUT (containing 30
red cell membrane proteins) has three unique entries. Our
MS-based dataset does not contain 27 members from the
CD list and six proteins from BGMUT (Figure 2C;
Supplementary Tables S3 and S4). Only further detailed
experiments by applying various methodologies may
help to resolve these inconsistencies. However, a properly
constructed database may significantly help to explore
these questions and promote further research in this
regard.
Generation of RBCC, an interactive database for
red cell membrane proteins
The use of the currently available resources is cumbersome
or not sufficient to identify a membrane protein in RBC as
a potential biomarker. Bioinformatics studies suffer from
identifying all RBC proteins from MS data sources (24).
To overcome these difficulties we have generated the
RBCC (Red Blood Cell Collection), a database and a web
application allowing the storing and accessing of all experi-
mentally identified RBCs proteins focusing the RBC mem-
brane proteins (http://rbcc.hegelab.org).
In this database, we have integrated knowledge from
various resources, including the hRBCD (7), reviews (6,
10), the BGMUT database of blood group system (19) and
the CD marker table provided by BD. Gene names and
preferentially UniProtKB IDs were identified either auto-
matically or manually. UniProtKB IDs are used in our
database to uniquely identify proteins, since UniProtKB is
currently one of the most stable and reliable protein
Figure 1. MS results of 3 independent red cell membrane samples. (A) These MS experiments were reproducible, as indicated by the high number
(304) of proteins identified in three individual experiments. (B, C) Detection of the RBC transmembrane and membrane-associated proteins was also
efficient. For methodological details see ‘Methods’ section.
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identification systems (18). Moreover, our data are
UniProtKB centred in a way that the basic properties of
proteins (e.g. name, function, genetic variants, cross-refer-
ences, etc.) are taken from this database, since it is a manu-
ally curated with high reliability.
The resulting RBCC database now contains 2638
unique protein entries, from which 846 are presumed
‘membrane’ proteins (either labelled as transmembrane or
membrane-associated proteins), and out of these 376 are
labelled as TM proteins, that contain predicted transmem-
brane regions. By default, the search function is currently
constrained to the ‘membrane’ proteins in the database.
One of the main purposes of a database design is to
help users with the ease of data accessibility. While it is
usually legitimate and necessary to create the data storage
in a relational database management system (RDBMS),
this implementation does not allow an easy, Google-like
search option—a problem faced on most of the biological
databases available on the Internet. To have an improved
and user-friendly search option (Supplementary Figure S2),
we have employed the full text search possibilities of the
RDBMS. In the result set and in the entry page of a protein
(Supplementary Figure S3) selected data fields of
UniProtKB are presented.
Since in many cases the data sought by the users may
not be present in UniProtKB, records from other databases
are also inserted into the RBCC database. As an example,
in order to help to find RBC membrane protein biomarkers
related to diseases, the OMIM (http://omim.org) records
for the identified RBC membrane proteins are also pre-
sented. In addition, in our database registered users can
make important comments (e.g. on quality of antibodies;
verification of the presence of a protein in RBC by bio-
chemical studies) which are also visible for following users.
In order to assess the genetic background of a selected
RBC membrane protein as a potential biomarker, our web
application lists the available genetic variants and also
hyperlinks to cross-references selected from UniProtKB. In
addition, we provide a link to Antibodypedia (25), con-
taining validated antibodies against proteins, that readily
aid the selection of an antibody to be tested in immunoede-
tection, e.g. by flow cytometry. Antibodypedia is an alter-
native of the CD antibody panels, containing also
validated antibodies for the human proteome, not exclu-
sively for the few hundred proteins in the CD system.
Comparative analysis of data for membrane
proteins in RBCs
Recent databases provided a surprisingly large number of
previously unexplored membrane proteins in the single
plasma membrane compartment of the human erythro-
cytes. Moreover, it has been suggested that the quantitative
expression levels of certain membrane proteins in the easily
accessible RBC are closely related to different disease con-
ditions (9, 26). However, when trying to analyse and com-
pare the available databases, we found an unexpected
confusion and lack of confidence for RBC membrane pro-
teins searches.
Therefore, we have performed an own MS study on the
isolated human RBC, and compared it with different avail-
able resources before assembling into a database for RBC
membrane proteins (http://rbcc.hegelab.org). As detailed
above, the current database containing 846 ‘membrane
protein’ entries, based on many of the above-mentioned
datasets, most probably represents an overestimation of
the potential RBC membrane protein constituent.
Therefore, we have also introduced ‘confidence’ levels to
evaluate the potential validity of the listed proteins. A low
level was set, if the protein was identified only semi-
automatically from reviews, in which case we are not able
to assess the quality of the large number of sources in these
review papers. A medium level was specified when the pro-
tein is present in either hRBCD (7), in the study of
Figure 2. Comparison of the coverage of RBC transmembrane and membrane-associated proteins in different datasets. (A) The presence of mem-
brane proteins in MS datasets, (B) in comprehensive reviews and (C) in highly validated data sources are compared with membrane proteins identi-
fied in our MS study. hRBCD, human RBC Database; Pesciotta et al., D’Alessandro et al., and Goodman et al. are references to (6, 10, 11); BGMUT and
BD_CD mark the human blood group database and the CD marker table provided by BD, respectively.
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Pesciotta et al. (11), or in our MS samples. We compared
the methodologies and the results of these MS studies and
drew the conclusion that the differences may arise from
problems of membrane protein MS (e.g. variability in pro-
tease accessibility or sample components caused by hydro-
phobic properties resulting in aggregation and/or adhesion
to tube walls). We defined a high confidence level, when
the protein was present in at least two MS studies [hRBCD
(7), PM22954596/Pesciotta et al. (11), and our work] or is
an established blood group or CD marker. Although this
is only a temporary, coarse-grained setting of confidence
levels in the database, this approach and further related
studies may significantly help the decisions for selecting
RBC membrane proteins as possible targets for research or
diagnostic markers.
In order to allow assessing whether or not a protein is a
candidate diagnostic biomarker, we have extended the
RBCC database to cover the available data for membrane
protein function, the variability of the genetic background
as well as the relationship with genetically determined
human diseases. Thus, the RBCC protein database and its
search and command options presented here may signifi-
cantly help the current, accelerated development of new
biomarkers helping both stratified/personalized diagnostics
and therapy.
This database now contains an unexpected large num-
ber of validated membrane proteins previously thought to
be specific for selected tissues and calls attention to RBC
proteins related to major human diseases. As examples,
among the RBC membrane proteins we find key ABC
transporters (e.g. ABCC1-MRP1, ABCC4-MRP4, ABCG2-
BCRP), more than 20 different solute carrier (SLC) type
transporters, and an important copper-transporting
ATPase. Virus and other infectious agent receptors, pro-
teins involved in membrane lipid organization and modu-
lation (e.g. phospholipid transporters and scramblases),
signal transduction-related proteins (e.g. interleukin recep-
tors, RAS proteins, LIF receptor, G-protein regulated pro-
tein kinases, PI and PIP kinases, RAB, RAC, RAP and RAS
proteins), membrane scaffolding, trafficking and cell adhe-
sion proteins (e.g. flotillin 1 and 2, syntaxins, basigin,
VCAM, ICAM) are also present with ‘high confidence’.
Many of the proteins identified in red cell membrane
are involved in the development of either monogenic or
polygenic diseases, e.g. proteins related to Alzheimer dis-
ease (e.g. the amyloid beta protein, alpha-synuclein, amyl-
oid beta precursor protein-binding protein 1, clusterin,
presenilin-1; nicastrin, acetylcholinesterase, basigin,
protein disulfide-isomerase), to metabolic syndromes
(e.g. GLUT1, GLUT3, GLUT4, urea transporters, ferro-
portin, ABCG2, monocarboxylate transporter, aquaporins,
cAMP-dependent protein kinase, G-protein subunits,
diacylglycerol kinase, RHO kinases, nicastrin), or to
hypertension (e.g. glucose transporters, the Band3
anion transporter, the K-Cl co-transporter 3, the
KCNN4-Gardos channel, aquaporin1, plasma membrane
ATPases, adducins, ankyrin, Hras, Kras and Nras, G alpha
protein, IL receptors, dynamin, interferon and TNF recep-
tors). A follow-up study exploring the quantitative expres-
sion of the RBC membrane proteins, as already performed
for ABCG2 (26), may provide key information regarding
some of the above-listed candidates.
A reference RBC proteome and known caveats in deter-
mining the RBC proteome would be important also for
therapeutic developments, involving erythrocytes gener-
ated from induced pluripotent stem cells (iPSC) (27).
Although comparison of iPSC-derived erythroid cells to
erythrocytes indicated highly overlapping proteomes, a
significant number of both soluble and membrane proteins
(e.g. CD44 responsible for the Indian blood group system,
PMCA4, ABCG2) were not identified in cell lines in this
MS-based study. These difficulties could lead to misinter-
pretation of the similarity levels (proteins present in the
reference cell line but not detected and absent in the iPSC-
derived erythroid cells), thus may result in false directions
in therapeutic developments.
It is interesting to note that when performing the ana-
lysis of our extended database, we did not find several clin-
ically important membrane proteins, indicated by
numerous earlier studies to be present in the erythrocyte
membrane. There are several examples of such ‘outliers’,
including the insulin receptor, the beta adrenergic receptor
and several ABC and SLC transporters. This may be a hint
that even large-scale proteomic studies may miss important
information and further results of biochemical, genetic and
immunological studies should be combined to have a com-
plete knowledge in this regard. In order to compensate for
this clearly incomplete feature of the current RBC data-
bases, we provided an ‘open correctibility’ function in this
database, so that the content of the database can be
updated based on comments from registered users.
Conclusions
Numerous human membrane proteins became accepted
clinical biomarkers and the determination of the easily
accessible RBC membrane proteins may provide new diag-
nostic possibilities in this regard. Since the current data-
bases including our membrane specific proteomics
presented in this study show large variations, we generated
a comprehensive and expandable database for the RBC
membrane proteins. The integrated web database now
refers to proteomic, genetic and medical databases as well,
and contains an unexpected large number of validated
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RBC membrane proteins previously thought to be specific
for other tissues and/or related to major human diseases.
This study should facilitate the development of RBC mem-
brane biomarker platforms and provide a unique resource
to aid further research and diagnostics.
Supplementary Data
Supplementary data are available at Database Online.
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